Spermosens AB Earnings Call Transcripts

Fiscal Year 2026

Status update

Product is ready for clinical validation and regulatory steps, with strong partner interest and a unique market position. Financial runway extends to late July, with licensing deals targeted for H2 2026 and no current plans for rights issues. Ongoing strategic focus is on partnerships, cost control, and value creation.

Read full transcript →